Partners Portal Contact

New publication on the mode of action of Mucoprotectants: gelatin tannate and xyloglucan show similar effectivity on preventing Cholera Toxin-Induced diarrhea in experimental studies1

The newer antidiarrheal agents include the mucoprotectants gelatin tannate and xyloglucan. Both were able to attenuate cholera toxin-induced intra-loop water secretion in an experimental study in rats. This supports previous evidence that their mechanism of mucosal protection is closely related to their chemical structures, and involves the ability to form [...]

Read More
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner…

Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys

Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants. XILAPLUS® is a class III medical device and complies with the [...]

Read More

We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children”

Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715. Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715. [...]

Read More

Launch of TASECTAN® AF in Denmark

Noventure is glad to announce the launch of TASECTAN® AF in Denmark by its partner company Pharmaforce, thus setting a record time-to-market, after Noventure granted Pharmaforce exclusive distribution right for Tasectan® AF in the Nordic markets last April. Tasectan® AF is intended to restore the physiological functions of the intestinal [...]

Read More

Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland and Norway.

Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different [...]

Read More
Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them [...]

Read More
Noventure | New scientific publication on Mucoprotection and diarrheal processes.

New scientific publication on Mucoprotection and diarrheal processes.

Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6  Expert Opin Investig Drugs. 2017 Dec 26:1-6.   NO ABSTRACT AVAILABLE Mucoprotectans chapter: 4. Mucosal protective agents Clarifying the role of intestinal mucus in reducing inflammation and infection has led to the [...]

Read More
Noventure | The role of mucoprotectants in the management of gastrointestinal disorders.

The role of mucoprotectants in the management of gastrointestinal disorders.

Eutamene, Beaufrand Harkat  C, Theodorou V. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018 ABSTRACT Introduction: The intestinal barrier controls the absorption of nutrients and water whilst helping to prevent the entry of toxins and pathogenic micro-organisms from the lumen into the tissues. Deficiencies in the barrier are associated with various [...]

Read More